Contraception Language in Informed Consent Forms: A Survey of Biopharmaceutical Companies

被引:2
作者
Ng, Eric W. [1 ]
Chiruvolu, Padmaja [2 ]
Levy, Gweneth F. [3 ]
Allan, Brent R. [4 ]
Wyszynski, Diego F. [1 ]
机构
[1] Amgen Inc, Maternal & Pediat Safety, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Biostat, Thousand Oaks, CA 91320 USA
[3] Amgen Inc, Med Safety Review Team, Thousand Oaks, CA 91320 USA
[4] Amgen Inc, Med Assessment Safety Team, Thousand Oaks, CA 91320 USA
来源
DRUG INFORMATION JOURNAL | 2012年 / 46卷 / 03期
关键词
clinical trial; contraception; drug industry; informed consent; pregnancy; WOMEN; ISSUES;
D O I
10.1177/0092861512438747
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Although contraception language is typically required in subject informed consent forms (ICFs) used in clinical trials, there are no regulatory guidelines on the type and duration of methods of contraception that should be used. The authors conducted an anonymous 3-part survey to assess what contraception language biopharmaceutical companies use in their ICFs as well as the staff composition of the companies' pharmacovigilance teams dealing with pregnancy and lactation. The majority of the companies sponsor clinical trials involving either small molecules (drugs) or a mix of small and large (biologics) molecules. The survey showed notably different answers between companies. Also, only a few companies have staff specifically dedicated to overseeing the enrollment of women of childbearing potential and following their progress if they become pregnant. The findings from this survey indicate that there is little uniformity among biopharmaceutical companies with respect to the contraception language included in ICFs.
引用
收藏
页码:329 / 335
页数:7
相关论文
共 17 条
  • [1] [Anonymous], 2004, Selected Practice Recommendations for Contraceptive Use
  • [2] [Anonymous], 2010, BIRTH CONTR GUID
  • [3] The ethics of excluding women who become pregnant while participating in clinical trials of anti-epileptic medications
    Beran, Roy G.
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2006, 15 (08): : 563 - 570
  • [4] Contraceptive requirements for clinical research
    Cain, J
    Lowell, J
    Thorndyke, L
    Localio, AR
    [J]. OBSTETRICS AND GYNECOLOGY, 2000, 95 (06) : 861 - 866
  • [5] Paternal exposure and counselling: Experience of a Teratology Information Service
    De Santis, Marco
    Cesari, Elena
    Cavaliere, Annafranca
    Ligato, Maria Serena
    Nobili, Elena
    Visconti, Daniela
    Caruso, Alessandro
    [J]. REPRODUCTIVE TOXICOLOGY, 2008, 26 (01) : 42 - 46
  • [6] European Medicines Agency, 2005, GUID EXP MED PROD PR
  • [7] Disparities in rates of unintended pregnancy in the United States, 1994 and 2001
    Finer, Larence B.
    Henshaw, Stanley K.
    [J]. PERSPECTIVES ON SEXUAL AND REPRODUCTIVE HEALTH, 2006, 38 (02) : 90 - 96
  • [8] Paternal exposures: Impact on reproductive and developmental outcome, an overview
    Friedler, G
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1996, 55 (04) : 691 - 700
  • [9] International Conference on Harmonisation, 2009, NONCL SAF STUD COND
  • [10] International Conference on Harmonisation, 2005, CLIN SAF DAT MAN PER